Drug Profile
Research programme: covalent inhibitors - Aurigene Oncology
Alternative Names: AU-002; CDK12 inhibitors; CDK7 inhibitor; KRAS inhibitor; MALT-1 inhibitorLatest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action CD7 antigen inhibitors; Cyclin-dependent kinase inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; KRAS protein inhibitors; MALT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Cancer in India (PO)
- 28 May 2020 No recent reports of development identified for preclinical development in Cancer in India (PO)
- 26 Oct 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)